- ALNY +4.18%
Gear Up for Alnylam (ALNY) Q1 Earnings: Wall Street Estimates for Key Metrics
Yahoo Finance · 2 days ago
Open | 144.21 |
High | 151.95 |
Low | 143.96 |
Mkt Cap | 18.96B |
P/E (TTM) | N/A |
Div & Yield | N/A & N/A |
Prev. Close | 143.95 |
52 Wk. Low | 141.98 |
52 Wk. High | 218.88 |
Related stocks
Biopharmaceutical company
Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference therapeutics for genetically defined diseases. Wikipedia
(USD) | Q4 2023 | Y/Y |
---|---|---|
Revenue | 439.72M | 31.20% ▲ |
Net Income | -137.87M | - |
Diluted EPS | -1.10 | - |
Quarter | EPS Estimate | EPS Actual |
---|---|---|
Q1 2024 | -$1.18 | - |
Q4 2023 | -$1.32 | -$1.10 |
Q3 2023 | -$1.34 | $1.15 |
S&P FuturesES=F | 5,078.25+31.75 (+0.63%) |
Dow FuturesYM=F | 38,227.00+158.00 (+0.42%) |
Nasdaq FuturesNQ=F | 17,581.25+143.00 (+0.82%) |
Carvana Co.CVNA | 87.09+5.03% |
129.21+0.70% | |
NIO Inc.NIO | 5.27+11.65% |